Abstract
Abstract
Background
Depending on the treatment to be investigated, a clinical trial could be designed to assess objectives of superiority, equivalence or non-inferiority. The design of the study is affected by many different elements including the control treatment, the primary outcome and associated relationships.
In some studies, there could be more than one outcome of interest. In these situations, benefit-risk methodologies could be used to assess the outcomes simultaneously and consider the trade-off between the benefits against the risks of a treatment.
Benefit-risk is used within the regulatory industry but seldom included within publicly funded clinical trials within the UK. This project aims to gain an expert consensus on how to select the appropriate trial design (e.g. superiority) and when to consider including benefit-risk methods.
Methods
The project will consist of four work packages:
A web-based survey to elicit current experiences and opinions,
A rapid literature review to assess any current recommendations,
A two-day consensus workshop to gain agreement on the recommendations, and
Production of a guidance document.
Discussion
The aim of the project is to provide a guideline for clinical researchers, grant funding bodies and reviewers for grant bodies for how to select the most appropriate trial design and when it is appropriate to consider using benefit-risk methods. The focus of the guideline will be on publicly funded trials however, the vision is that the work will be applicable across research settings and we will connect with other organisations and committees as appropriate.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Medicine (miscellaneous)
Reference19 articles.
1. Lesaffre E. Superiority, equivalence, and non-inferiority trials. Bulletin of the NYU Hospital for Joint Diseases. 2008;66(2):150–4.
2. Schumi J, Wittes TJ. Through the looking glass: understanding non-inferiority. Trials. 2011;12(106):1–12 http://www.trialsjournal.com/content/12/1/106.
3. European Patients’ Academy. Benefit-Risk Assessment - EUPATI [Internet]. [cited 2019 Jul 15]. Available from: https://www.eupati.eu/glossary/benefit-risk-assessment/.
4. Mühlbacher AC, Juhnke C, Beyer AR, Garner S. Patient-focused benefit-risk analysis to inform regulatory decisions: the European Union perspective. Value in Health. 2016;19:734–40.
5. (EMA) EMA. Benefit-risk methodology. [Internet]. [cited 2019 Jul 26]. Available from: https://www.ema.europa.eu/en/about-us/support-research/benefit-risk-methodology